Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Cyrus Biotechnology sells software and consulting services that help drug and industrial companies design better proteins.
Proteins do most of the heavy lifting in our bodies, and they are increasingly the basis for modern medicines. Cyrus Biotechnology sells software and scientific help to companies that want to design or improve proteins for drugs and industrial uses. Its tools let researchers model and tweak protein structures on a computer before anyone sets foot in a lab, which saves time and money.
The company is built on a research platform that came out of the University of Washington's protein design work. Its main product, a software suite, lets scientists test thousands of possible protein changes virtually and pick the most promising ones. Cyrus sells subscriptions to that software and also takes on consulting projects, doing custom protein engineering for biopharma and industrial customers who need answers but don't want to build the expertise in-house. The business is a bet on a simple idea: designing proteins is hard, and most companies would rather rent expert tools than reinvent them. Cyrus competes for those customers against in-house teams and other computational biology software vendors. Its edge is a long track record in protein design research and a service model that pairs software with hands-on scientific help.
Cyrus is a private company, so its finances aren't public, and it isn't a household name even in biotech. That makes it a small, specialized player in a field where the big money goes to the drugs that eventually reach patients. But as protein-based medicines keep growing, the pick-and-shovel work of designing those proteins has to happen somewhere.
Saved answer · last researched 15 Nov 2026